Cardiovascular co-morbidity in cancer patients: the role of psychological distress
Cardio-Oncology volume 2, Article number: 9 (2016)
Due to aging of the population and cardiotoxic cancer treatment, there is an increasing group of patients with cancer and co-morbid cardiovascular disease (CVD). In order to find a balance between the risk of undertreating the malignancy on the one hand and inducing CVD on the other hand, CVD risk stratification at the time of cancer diagnosis and knowledge on the pathway for developing incident CVD in cancer patients is vital. In this paper, we propose an adapted multiple-hit hypothesis for developing CVD in cancer patients describing that patients with cancer are exposed to a series of sequential or concurrent events that together make them more vulnerable to reduced cardiovascular reserves, development of incident CVD and ultimately death. We highlight the possible impact of psychological distress secondary to a cancer diagnosis and/or treatment, which in turn may increase the risk of incident CVD in patients diagnosed with cancer. Furthermore, we discuss potential behavioral and pathophysiological mechanisms underlying the link between psychological distress and the pathophysiology of incident CVD. In addition, key unanswered questions for future research are posed. In the future, researching the adapted multiple-hit hypothesis for developing CVD among cancer patients will hopefully advance the care of cancer patients by finding some of the missing pieces of the puzzle. To do so, we need to focus on minimizing cardiovascular risk and promoting cardiovascular health in cancer patients by addressing the knowledge gaps formulated in this paper.
Cardiovascular co-morbidity in cancer patients
Due to aging of the population, there is an increasing number of patients with cancer and co-morbid cardiovascular disease (CVD). Additionally, cancer patients may develop incident CVD as a result of the cardiotoxicity of cancer treatment. Fortunately, there has been increasing awareness of co-morbid CVD in cancer patients. In 2009, the International CardiOncology Society (ICOS) was established . ICOS advocates a multi-disciplinary effort to combat CVD in cancer patients by both training oncologists and cardiologists and conducting multidisciplinary research. In 2014, during the international colloquium on cardio-oncology, ICOS stressed the importance of finding a balance between the risk of undertreating the malignancy on the one hand and inducing CVD by overtreating on the other hand . In order to accomplish this goal, they emphasize the importance of CVD risk stratification at the time of cancer diagnosis. Recommendations based on consensus have also been published to target the vulnerable cancer patient population, emphasizing the importance of a thorough cardiac evaluation, including the assessment of risk factors, prior to formulating a cancer treatment plan .
Adapted multiple-hit hypothesis: the impact of psychological distress
Important in CVD risk stratification is knowledge of the pathway for developing CVD in cancer patients. Within the field of cardio-oncology there is increasing interest in the multiple-hit hypothesis for developing CVD in cancer patients. This hypothesis was first described by Jones et al. in 2007 , and proposes that patients with cancer are exposed to a series of sequential or concurrent events that together make them more vulnerable to reduced cardiovascular reserves, development of incident CVD and ultimately death. With new developments in the field of cardio-oncology and by including knowledge on psychological distress as a risk factor for the pathogenesis of CVD in non-cancer populations, we have adapted the multiple-hit hypothesis (Fig. 1). In this paper, we will describe the adapted hypothesis in more detail, focusing on psychological distress secondary to a cancer diagnosis and/or treatment, which in turn may increase the risk of incident CVD in patients diagnosed with cancer. In the model, depicted arrows represent the most dominant associations, although many other relations exist. It should be noted that the current model depicted in Fig. 1 is a necessary simplification as various factors are associated with one another. To maintain comprehensibility of the model, not all associations will be explicitly depicted in the model, yet many of these associations are addressed throughout the paper.
Cancer treatment (a)
Cancer treatment consists of radiation, chemo-, hormone, targeted-, or immunotherapy or a combination of those. Some of these cancer treatments are cardiotoxic. Chemotherapy with anthracyclines as well as radiation to the chest in treating lymphomas or breast cancer are two examples of cardiotoxic cancer treatments [5, 6]. These cardiotoxic treatments can lead to reduced cardiovascular reserves and ultimately a heterogeneous group of CVDs ranging from benign to potentially lethal, represented by the unidirectional arrow ‘a’ (Fig. 1) [7, 8]. CVDs that have been associated with cancer treatments include thrombosis, electrocardiographic changes, arrhythmias, myopericarditis, myocardial infarction, cardiomyopathy, valvular heart disease, and congestive heart failure [5, 6]. These CVDs can occur within days, weeks, months or years after treatment . Some CVDs are relatively treatment-specific. For example, heart failure is common as a sequel to treatment with anthracyclines , whereas thoracic radiation to the left side of the chest involving the heart has been associated with risk of valvular stenosis, restrictive cardiomyopathy, pericarditis, and myocardial infarction post treatment .
CVD risk factors (b)
We view the relation between cancer treatment and CVD risk factors as bidirectional (arrow b1), with CVD risk factors leading to decreased cardiovascular reserves, CVD and mortality (unidirectional arrow b2). Having one or more CVD risk factors, such as older age and morbidities like hypertension or diabetes mellitus  prior to cancer diagnosis, affect cancer treatment options, often resulting in the use of less aggressive cancer treatment . We believe that in light of the multiple-hit hypothesis, the presence of CVD risk factors may also be viewed as secondary to cancer treatment: Cancer treatments can induce CVD risk factors such as hypertension  and diabetes mellitus , decreasing cancer patients’ cardiovascular reserve and enhancing their risk of incident CVD and mortality. Additionally the effect of CVD risk factors may be enhanced or diminished by lifestyle factors such as impaired or increased physical activity or psychological distress like depressive symptoms (these associations are not depicted in the model). The direct effects of both lifestyle factors and psychological distress on the pathogenesis of CVD in cancer patients will be discussed below.
Lifestyle factors (c)
Due to cancer and the intense nature of its treatment, patients may develop unhealthy lifestyles, including weight loss and physical inactivity, which may decrease their cardiac reserve and enhance their risk of CVD and mortality (depicted by the unidirectional arrows c1 and c2).
Psychological distress (d)
Research on risk factors for the development and progression of CVD among non-cancer populations has shown that next to CVD risk factors like hypertension, the mere presence of psychological distress is bad for patients’ health outcomes. Symptoms of depression, anxiety, specific personality traits, and fatigue have all been shown to predict the onset of CVD and the prognosis in patients with established CVD, independent of traditional biomedical risk factors [13–21]. A recent meta-analysis based on 20 studies examining the predictive value of anxiety for the incidence of coronary heart disease in originally healthy individuals found that anxious people had a 26% increased risk of developing coronary heart disease and a 48% increased risk of cardiac death . The so-called Type D (‘distressed’) personality has been consistently associated with poor outcomes in CVD-patients, as indicated in a recent meta-analysis . Individuals with a Type D personality are characterized by a high score on both negative affectivity and social inhibition. Negative affect is the tendency to experience negative emotions, whereas social inhibition is the tendency to inhibit emotions and to experience a high level of insecurity in social encounters . Also fatigue is predictive of new onset CVD in healthy individuals [16, 17] and coronary artery disease in CVD patients . The psychosocial risk factor that has been studied the most is depression, with evidence pointing to a relation between depression and the development of new onset CVDs, such as heart failure [19, 20], increased risk of major adverse cardiac events [20, 21], and cardiac death in patients with established CVD .
It is well-known that suffering from cancer and additionally undergoing cancer treatment has a major impact on patients’ lives, with the majority of cancer patients experiencing psychological problems, such as feelings of anxiety, fatigue and depression [23, 24]. Moreover, one in 5 cancer patients have a Type D personality . Hence, cancer patients may have an increased risk for onset CVD by these elevated levels of psychological distress after cancer diagnosis alone. It is important to note, however, that psychological distress could also be present prior to cancer diagnosis or throughout cancer treatment. Hence, some individuals may have already been at risk of developing CVD prior to being diagnosed or treated for cancer due to their prior experienced level of distress.
In 2007, when the original multiple-hit hypothesis was proposed, little was known about the potential putative role of psychological factors in CVD. Only in 2012, the European Society of Cardiology included psychosocial risk factors (e.g. depression and anxiety) in the Guidelines on Cardiovascular Disease Prevention in Clinical Practice for the first time . In 2014, the American Heart Association followed with a Scientific Statement advocating that depression be given risk factor status at the same level as traditional risk factors, due to considerable evidence that depression is linked not only to CVD prognosis but also that depression is a risk factor for incident CVD . More recent evidence implicating psychological distress as a risk factor for CVD and the fact that cancer patients experience high levels of psychological distress has inspired us to adapt the current multiple-hit hypothesis. In addition to including the causal effect of cancer diagnosis and treatment on experiencing psychological distress (unidirectional arrows d1a and d1b), we added the bidirectional relation between psychological distress and decreased cardiovascular reserve, CVD and mortality (bidirectional arrow d2), as psychological distress is not only a risk factor for incident CVD but is also increased in cancer patients who have co-morbid CVD.
Behavioral and pathophysiological mechanisms involved in psychological distress as a risk factor
The literature on the role of psychological distress in the pathogenesis of CVD among non-cancer populations has suggested that various mechanisms - both of behavioral and pathophysiological nature - are involved. With respect to behavioral mechanisms, anxiety, Type D personality, and depression have been related to unhealthy lifestyles, such as smoking, poor treatment adherence and bad consultation behavior [28–34]. Alternatively, lifestyle factors such as increased physical activity have been associated with lower levels of psychological distress, such as symptoms of depression .
With respect to pathophysiological mechanisms, platelet dysfunction, autonomic nervous system dysregulation, hypothalamic-pituitary-adrenal-axis (HPA-axis) dysregulation, cellular ageing, and inflammatory activation have been suggested to be involved in the relation between psychological risk factors and CVDs. Platelet activation is increased in patients with depression . Furthermore, thrombus formation on the surface of coronary plaque is key in acute coronary events, making platelet dysfunction a plausible mechanism . In addition, patients with feelings of anxiety, depression, fatigue and a Type D personality have reduced heart rate variability (HRV) [38–41], which is an indicator of cardiac autonomic control and predictive of cardiovascular morbidity and mortality [42, 43]. Furthermore, the HPA-axis is known to play a role in CVD . This system is vital for the regulation of the physiological reaction to stress, via the hormone cortisol, among others. Depressed, anxious, fatigued and Type D patients show elevated cortisol levels [44–47], suggesting that HPA-axis dysregulation is a possible mechanism. Likewise, anxiety and depression are related to shorter telomere length [48–50], a biomarker of cellular aging, which is in turn involved in the pathogenesis of CVD . Finally, depression, anxiety, fatigue, and Type D personality have been associated with elevated levels of pro-inflammatory cytokines (e.g. interleukin-1 (IL), IL-6, TNF-alpha, and its soluble receptors sTNFR1 and sTNFR2) [52–55]. In turn, these cytokines are involved in the pathogenesis of CVDs, such as heart failure .
Research agenda to study the adapted multiple-hit hypothesis
To date, there is limited research on the multiple-hit hypothesis for the development of CVD in cancer patients. Hence, there is an urgent need for research on the impact of psychological distress on incident CVD among cancer patients and the potentially additive or synergistic effects of cardiotoxic treatment, CVD risk factors, lifestyle factors and psychological distress, as described in the multiple-hit hypothesis. This knowledge will aid in risk stratification at the time of cancer diagnosis in order to (i) determine the appropriate cancer therapy and provide individually tailored treatment to decrease the risk of incident CVD, and (ii) identify patients at risk of incident CVD who could benefit from a disease management program to minimize the impact of CVD risk factors and psychological distress. For example, when treating a cancer patient with depression one would not only treat the depression but also reduce CVD risk and thus improve the patient’s quality of life and general health outcomes. Knowledge of the underlying behavioral and pathophysiological mechanisms is essential as it provides insight into understanding these relations, ultimately providing targets for intervention. In addition, information on clinical and patient-reported outcomes of cancer patients with co-morbid CVD will help tailor future care for this vulnerable patient group.
To answer these questions we can use various data sources, such as: (a) newly developed longitudinal in-depth data collections; (b) large population-based longitudinal aging studies; and (c) existing databases. Ideally, newly developed longitudinal in-depth data collections with long-term follow-up should be initiated, enabling a sufficient number of CVD events to occur. These studies should include information on all the aspects described in the multiple-hit hypothesis (i.e., type of cancer treatment, CVD risk factors, lifestyle factors, psychological distress, cardiovascular reserves, co-morbid CVD and mortality). Moreover, information on pathophysiological mechanisms, such as markers of inflammation or cellular aging, should be collected to gain insight into underlying mechanisms. By following oncology patients, one could examine the specific cardiotoxic effects and their interaction with CVD risk factors, lifestyle factors and psychological distress. Furthermore, large population-based longitudinal aging studies including originally healthy individuals would enable the identification of risk factors common to both cancer and CVD. It would also allow the examination of CVD risk factors present prior to a cancer diagnosis as healthy non-cancer patients would be included and followed over time until they first develop cancer and then pose the risk of developing CVD. These healthy individuals moreover offer matched cancer-free controls for each cancer patient as a reference group. Existing databases also offer unique opportunities to study parts of the research questions that can be extracted from our adapted multiple-hit hypothesis. For example, in the Netherlands, information from the southern region Netherlands Cancer Registry is linked to the PHARMO database network . The population-based Netherlands Cancer Registry includes clinical information on type of malignancy, date of diagnosis and type of primary cancer treatment for all newly diagnosed cancer patients in the Netherlands. The PHARMO database is a network of electronic healthcare databases and combines data from primary and secondary healthcare settings in the Netherlands. Information on hospitalizations and drug dispensing records from the PHARMO database can be used to determine whether someone has co-morbid CVD, CVD risk factors (e.g. hypertension) or have a severe mental condition (e.g. clinical depression). These linked databases enable us to examine associations between cardiotoxic cancer treatment, CVD risk factors and psychological distress and their effect on the development of co-morbid CVD.
In conclusion, by researching the adapted multiple-hit hypothesis for developing CVD among cancer patients, we hope to find some of the missing pieces of the puzzle. Our ultimate goal is to advance the care of cancer patients. Therefore, we need to focus on the minimization of cardiovascular risk and promotion of cardiovascular health in cancer patients by addressing the knowledge gaps, as formulated above.
Heart rate variability
International CardiOncology Society
Lenihan DJ, Cardinale D, Cipolla CM. The compelling need for a cardiology and oncology partnership and the birth of the International CardiOncology Society. Prog Cardiovasc Dis. 2010;53:88–93.
Ewer M, Gianni L, Pane F, Sandri MT, Steiner RK, Wojnowski L, et al. Report on the international colloquium on cardio-oncology (rome, 12–14 march 2014). Ecancermedicalscience. 2014;8:433. doi:10.3332/ecancer.2014.433.
Kawecka-Jaszcz K, Bednarek A. The management of cancer patients with heart disease. Przegl Lek. 2012;69:82–6.
Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007;50:1435–41. doi:10.1016/j.jacc.2007.06.037.
Geiger S, Lange V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs. 2010;21:578–90. doi:10.1097/CAD.0b013e3283394624.
Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004;30:181–91. doi:10.1016/j.ctrv.2003.07.003.
Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104:357–70. doi:10.1093/jnci/djr533.
Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21:3431–9. doi:10.1200/JCO.2003.07.131.
He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med. 2001;161:996–1002.
Janssen-Heijnen ML, Szerencsi K, van de Schans SA, Maas HA, Widdershoven JW, Coebergh JW. Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity. Crit Rev Oncol Hematol. 2010;76:196–207. doi:10.1016/j.critrevonc.2009.11.004.
Qi WX, Shen Z, Tang LN, Yao Y. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Investig. 2014;34:231–40. doi:10.1007/s40261-014-0174-5.
Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56. doi:10.1200/JCO.2006.06.2497.
Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99:2192–217.
Roest AM, Martens EJ, de JP, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol. 2010;56:38–46.
O'Dell KR, Masters KS, Spielmans GI, Maisto SA. Does type-D personality predict outcomes among patients with cardiovascular disease? A meta-analytic review. J Psychosom Res. 2011;71:199–206.
Ekmann A, Osler M, Avlund K. The predictive value of fatigue for nonfatal ischemic heart disease and all-cause mortality. Psychosom Med. 2012;74:464–70.
Ekmann A, Petersen I, Manty M, Christensen K, Avlund K. Fatigue, general health, and ischemic heart disease in older adults. J Gerontol A Biol Sci Med Sci. 2012. doi:10.1093/gerona/gls180.
Kop WJ, Appels AP, Leon de Mendes CF, de Swart HB, Bar FW. Vital exhaustion predicts new cardiac events after successful coronary angioplasty. Psychosom Med. 1994;56:281–7.
Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. Int J Geriatr Psychiatry. 2007;22:613–26.
Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.
Frasure-Smith N, Lesperance F. Reflections on depression as a cardiac risk factor. Psychosom Med. 2005;67 Suppl 1:S19–25.
Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67:89–97.
Merckaert I, Libert Y, Messin S, Milani M, Slachmuylder JL, Razavi D. Cancer patients’ desire for psychological support: prevalence and implications for screening patients’ psychological needs. Psychooncology. 2010;19:141–9.
Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008;112:2577–92.
Mols F, Thong MS, van de Poll-Franse LV, Roukema JA, Denollet J. Type D (distressed) personality is associated with poor quality of life and mental health among 3080 cancer survivors. J Affect Disord. 2012;136:26–34.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012;19:403–88. doi:10.1007/s12529-012-9242-5.
Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129:1350–69. doi:10.1161/CIR.0000000000000019.
Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol. 1995;14:88–90.
Glassman AH, Helzer JE, Covey LS, Cottler LB, Stetner F, Tipp JE, et al. Smoking, smoking cessation, and major depression. JAMA. 1990;264:1546–9.
Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, Stampfer MJ, et al. Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation. 1994;89:1992–7.
Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation. 1994;90:2225–9.
Schoormans D, Mulder BJ, van Melle JP, Pieper EG, van Dijk AP, Sieswerda GJ, et al. Patients with a congenital heart defect and Type D personality feel functionally more impaired, report a poorer health status and quality of life, but use less healthcare. Eur J Cardiovasc Nurs. 2012;11:349–55. doi:10.1177/1474515112437828.
DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.
Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326–7.
Rebar AL, Stanton R, Geard D, Short C, Duncan MJ, Vandelanotte C. A meta-meta-analysis of the effect of physical activity on depression and anxiety in non-clinical adult populations. Health Psychol Rev. 2015;9:366–78. doi:10.1080/17437199.2015.1022901.
Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry. 2000;57:875–82.
Kent LK, Shapiro PA. Depression and related psychological factors in heart disease. Harv Rev Psychiatry. 2009;17:377–88.
Watkins LL, Grossman P, Krishnan R, Blumenthal JA. Anxiety reduces baroreflex cardiac control in older adults with major depression. Psychosom Med. 1999;61:334–40.
Carney RM, Freedland KE, Stein PK, Skala JA, Hoffman P, Jaffe AS. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. Psychosom Med. 2000;62:639–47.
Fagundes CP, Murray DM, Hwang BS, Gouin JP, Thayer JF, Sollers III JJ, et al. Sympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a physiological substrate in cancer survivors. Psychoneuroendocrinology. 2011;36:1137–47.
Martin LA, Doster JA, Critelli JW, Lambert PL, Purdum M, Powers C, et al. Ethnicity and Type D personality as predictors of heart rate variability. Int J Psychophysiol. 2010;76:118–21.
Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: the ARIC Study. Atherosclerosis Risk In Communities. Circulation. 2000;102:1239–44.
Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011;58:745–50.
Molloy GJ, Perkins-Porras L, Strike PC, Steptoe A. Type-D personality and cortisol in survivors of acute coronary syndrome. Psychosom Med. 2008;70:863–8.
Burke HM, Davis MC, Otte C, Mohr DC. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology. 2005;30:846–56.
Vreeburg SA, Zitman FG, van PJ, DeRijk RH, Verhagen JC, van DR, et al. Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom Med. 2010;72:340–7.
Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med. 2005;67:277–80.
Verhoeven JE, Revesz D, Epel ES, Lin J, Wolkowitz OM, Penninx BW. Major depressive disorder and accelerated cellular aging: results from a large psychiatric cohort study. Mol Psychiatry. 2014;19:895–901. doi:10.1038/mp.2013.151.
Verhoeven JE, Revesz D, van Oppen P, Epel ES, Wolkowitz OM, Penninx BW. Anxiety disorders and accelerated cellular ageing. Br J Psychiatry. 2015;206:371–8. doi:10.1192/bjp.bp.114.151027.
Verhoeven JE, Revesz D, Wolkowitz OM, Penninx BW. Cellular aging in depression: Permanent imprint or reversible process?: An overview of the current evidence, mechanistic pathways, and targets for interventions. Bioessays. 2014;36:968–78. doi:10.1002/bies.201400068.
Zhu H, Belcher M, van der Harst P. Healthy aging and disease: role for telomere biology? Clin Sci. 2011;120:427–40. doi:10.1042/CS20100385.
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–57.
O'Donovan A, Hughes BM, Slavich GM, Lynch L, Cronin MT, O'Farrelly C, et al. Clinical anxiety, cortisol and interleukin-6: evidence for specificity in emotion-biology relationships. Brain BehavImmun. 2010;24:1074–7.
Conraads VM, Denollet J, De Clerck LS, Stevens WJ, Bridts C, Vrints CJ. Type D personality is associated with increased levels of tumour necrosis factor (TNF)-alpha and TNF-alpha receptors in chronic heart failure. Int J Cardiol. 2006;113:34–8.
Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64:604–11.
Dibbs Z, Kurrelmeyer K, Kalra D, Seta Y, Wang F, Bozkurt B, et al. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians. 1999;111:423–8.
van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer. 2010;46:395–404.
This study was partly funded by a Social Psychology Fellowship from the Dutch Cancer Society (grant number #UVT2013-5893) granted to Dounya Schoormans.
Availability of data and material
All authors contributed to the planning and writing of this manuscript. All authors have read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
About this article
Cite this article
Schoormans, D., Pedersen, S.S., Dalton, S. et al. Cardiovascular co-morbidity in cancer patients: the role of psychological distress. Cardio-Oncology 2, 9 (2016). https://doi.org/10.1186/s40959-016-0019-x
- Psychological distress